登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
ClinicalTrials.gov 上登记的一项肺癌开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06517953,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Pathologically confirmed adenocarcinoma of the lung, with locally advanced or metastatic disease and not amenable to curative surgery or radiotherapy (stage IIIB, IIIC or IV disease based on the eighth edition of the American Joint Committee on Cancer (AJCC) TNM classification). Patients with mixed histology are eligible if adenocarcinoma is the predominant histology.
入选标准第 2 条
Tissue or blood samples are confirmed by the central laboratory or research center as rare EGFR mutations, including exon 18 G719X, S768I in exon 20 and at least one of the L861Q mutations in exon 21;
入选标准第 4 条
Patients must be treatment-naive for locally advanced or metastatic NSCLC systemic antitumor therapy. Prior adjuvant and neo-adjuvant therapy (except for EGFR-TKIs) is permitted if have been completed at least 6 months prior to initiation of disease progression.
入选标准第 3 条
Agree to use effective contraception during the study period and for at least 3 months after completion of the study treatment.
入选标准第 8 条
Previous traditional chinese medicine with an antitumor indication within 2 weeks before the first dose of study drug.
排除标准第 4 条
Previous major surgery within 4 weeks before the first dose of study drug,or planing to have major surgery during study.
排除标准第 5 条
Any unresolved toxicities from prior treatment greater than NCI CTCAE v4.03 grade 2 or higher.
排除标准第 7 条
Previous therapeutic clinical trial within 4 weeks before the first dose of study drug.
排除标准第 24 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
入选标准第 5 条
absolute neutrophil count(ANC)<1,500/mcL
排除标准第 15 条
platelets<100,000/mcL
排除标准第 16 条
hemoglobin<9.0 g/dL
排除标准第 17 条
AST/ALT>2.5 times the upper limit of normal (ULN)or >5 times the ULN in the presence of liver metastases
排除标准第 18 条
total bilirubin(TBIL)>1.5 times the ULN if no liver metastases or > 3 times the ULN in the presence of liver metastases
排除标准第 19 条
serum creatinine(SCr) >1.5 times the ULN or creatinine clearance ≥50 mL/min.
排除标准第 20 条
At least 1 measurable tumor lesion without radiotherapy as per RECIST v1.1.
入选标准第 7 条
Active infection including hepatitis B,hepatitis C,syphilis and human immunodeficiency virus (HIV).
排除标准第 10 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06517953,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
18 years of age or older. Pathologically confirmed adenocarcinoma of the lung, with locally advanced or metastatic disease and not amenable to curative surgery or radiotherapy (stage IIIB, IIIC or IV disease based on the eighth edition of the American Joint Committee on Cancer (AJCC) TNM classification). Patients with mixed histology are eligible if adenocarcinoma is the predominant histology. Patients must be treatment-naive for locally advanced or metastatic NSCLC systemic antitumor therapy. Prior adjuvant and neo-adjuvant therapy (except for EGFR-TKIs) is permitted if have been completed at least 6 months prior to initiation of disease progression. Tissue or blood samples are confirmed by the central laboratory or research center as rare EGFR mutations, including exon 18 G719X, S768I in exon 20 and at least one of the L861Q mutations in exon 21; Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Predicted survival ≥ 3 months. At least 1 measurable tumor lesion without radiotherapy as per RECIST v1.1. Agree to use effective contraception during the study period and for at least 3 months after completion of the study treatment. Provision of informed consent prior to any study procedure.排除标准:Exclusion Criteria:
Combined with other malignancy(except for clinically cured in situ cervix carcinoma, basal cell or squamous epithelial skin cancer,thyroid papillary carcinoma). Prior treatment with any EGFR-TKIs. Prior treatment with any systemic antitumor therapy for locally advanced or metastatic NSCLC. Previous traditional chinese medicine with an antitumor indication within 2 weeks before the first dose of study drug. Previous major surgery within 4 weeks before the first dose of study drug,or planing to have major surgery during study. Symptoms or signs worsened within 2 weeks before the first dose of study drug. Any unresolved toxicities from prior treatment greater than NCI CTCAE v4.03 grade 2 or higher. Spinal cord compression,symptomatic or unstable central nervous system (CNS) metastases that require the use of steroids .Patients who have a stable CNS status for at least 4 weeks before treatment will be allowed to join the study. Any clinical evidence of serious or uncontrolled systemic disease,including uncontrolled hypertension after drug treatment,active bleeding diatheses, previous or present thrombus,uncontrolled cardiovascular and cerebrovascular diseases. Active infection including hepatitis B,hepatitis C,syphilis and human immunodeficiency virus (HIV). Mean resting corrected QT interval (QTcF) ≥450 msec,obtained from 3 ECGs or any clinically important abnormalities in rhythm,conduction, morphology of resting ECG or left ventricular ejection fraction (LVEF) ≤ 50%,etc. Previous history of interstitial lung disease(ILD),drug-induced interstitial lung disease,history of radiation-induced pneumonia requiring hormone therapy,or clinical evidence of active interstitial lung disease. Any instance that affects the patient's ability to swallow drug or oral malabsorption. Occur any laboratory indicator abnormalities as follow: absolute neutrophil count(ANC)<1,500/mcL platelets<100,000/mcL hemoglobin<9.0 g/dL AST/ALT>2.5 times the upper limit of normal (ULN)or >5 times the ULN in the presence of liver metastases total bilirubin(TBIL)>1.5 times the ULN if no liver metastases or > 3 times the ULN in the presence of liver metastases serum creatinine(SCr) >1.5 times the ULN or creatinine clearance ≥50 mL/min. Patients with a known allergy or delayed hypersensitivity reaction to the any component of study drugs or their excipients. Within 1 week before the first dose of study drug currently receiving or need concomitant medications known to be potent inhibitors or inducers of CYP3A, CYP2D6,CYPC8 and CYP2C19,sensitive substrate of CYP3A and CYP2C9. Within 1 week before the first dose of study drug ongoing use of warfarin. Previous therapeutic clinical trial within 4 weeks before the first dose of study drug.
引自 ClinicalTrials.gov, NCT06517953, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06517953,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。